Profile - To The Moon

lcGoh

Posts · 118Posts · 118
Following · 0Following · 0
Followers · 0Followers · 0

- lcGohlcGoh
  ·2023-06-23
  U
  Sorry, this post has been deleted
  3.87K Comment
  Like
  Share
  Report
- lcGohlcGoh
  ·2023-06-23
  B
  Sorry, this post has been deleted
  4.43K Comment
  Like
  Share
  Report
- lcGohlcGoh
  ·2023-06-23
  B
  Wall Street can't sit still! New regulations of U.S. banking industry may be tougher than expected
  据六名知情人士透露，美国银行业正推动软化一项提高银行资本金要求的重大监管提案，担心该提案可能过于繁重，尤其是对仍未从3月银行业危机中恢复过来的银行而言。以美联储为首的银行监管机构正在敲定一项提案，该提
  Wall Street can't sit still! New regulations of U.S. banking industry may be tougher than expected
  4.00K Comment
  Like
  Share
  Report
- lcGohlcGoh
  ·2023-06-23
  N
  Sorry, this post has been deleted
  3.98K Comment
  Like
  Share
  Report
- lcGohlcGoh
  ·2023-06-23
  K
  Do not hesitate to destroy jobs? POWELL: Two more rate hike is appropriate
  尽管议员质疑美联储抗通胀可能破坏就业，但鲍威尔极力为进一步紧缩的立场辩护，此前又一鹰派现身支持.......周四，美联储主席鲍威尔出席众议院金融服务委员会听证会，发言稿与周三的证词一模一样。在问答环节
  Do not hesitate to destroy jobs? POWELL: Two more rate hike is appropriate
  3.51K Comment
  Like
  Share
  Report
- lcGohlcGoh
  ·2023-06-17
  H
  Sorry, this post has been deleted
  3.81K Comment
  Like
  Share
  Report
- lcGohlcGoh
  ·2023-06-17
  N
  Sorry, this post has been deleted
  3.77K Comment
  Like
  Share
  Report
- lcGohlcGoh
  ·2023-06-17
  O
  AbbVie and BeiGene: Can't step into the same river
  “专利，是给天才之火加上利润之油”，林肯的这句名言，被创新药领域的重磅炸弹药物一次次印证。药企之间，没有什么比一场成功的专利战，更能将对手一击致命。但同时，被狙击的一方，绝不会轻易束手就擒，往往会用尽
  AbbVie and BeiGene: Can't step into the same river
  3.75K Comment
  Like
  Share
  Report
- lcGohlcGoh
  ·2023-06-17
  M
  Sorry, this post has been deleted
  4.11K Comment
  Like
  Share
  Report
- lcGohlcGoh
  ·2023-06-17
  N
  Sorry, this post has been deleted
  4.40K Comment
  Like
  Share
  Report
No following yet

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3583111190875685","uuid":"3583111190875685","gmtCreate":1620018053186,"gmtModify":1655931331844,"name":"lcGoh","pinyin":"lcgoh","introduction":"","introductionEn":null,"signature":"","avatar":"https://community-static.tradeup.com/news/ea3d27fab7696dea29861dd0ec2eeec9","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":38,"tweetSize":118,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.06.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.06.12","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":190249042440240,"gmtCreate":1687473221441,"gmtModify":1687473224643,"author":{"id":"3583111190875685","authorId":"3583111190875685","name":"lcGoh","avatar":"https://community-static.tradeup.com/news/ea3d27fab7696dea29861dd0ec2eeec9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583111190875685","idStr":"3583111190875685"},"themes":[],"title":"","htmlText":"U","listText":"U","text":"U","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/190249042440240","repostId":"1175881376","repostType":4,"isVote":1,"tweetType":1,"viewCount":3867,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190248855609608,"gmtCreate":1687473207431,"gmtModify":1687473210898,"author":{"id":"3583111190875685","authorId":"3583111190875685","name":"lcGoh","avatar":"https://community-static.tradeup.com/news/ea3d27fab7696dea29861dd0ec2eeec9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583111190875685","idStr":"3583111190875685"},"themes":[],"title":"","htmlText":"B","listText":"B","text":"B","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/190248855609608","repostId":"2345757673","repostType":4,"isVote":1,"tweetType":1,"viewCount":4427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190248695894264,"gmtCreate":1687473161227,"gmtModify":1687473164766,"author":{"id":"3583111190875685","authorId":"3583111190875685","name":"lcGoh","avatar":"https://community-static.tradeup.com/news/ea3d27fab7696dea29861dd0ec2eeec9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583111190875685","idStr":"3583111190875685"},"themes":[],"title":"","htmlText":"B","listText":"B","text":"B","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/190248695894264","repostId":"2345500717","repostType":4,"repost":{"id":"2345500717","kind":"highlight","pubTimestamp":1687446683,"share":"https://ttm.financial/m/news/2345500717?lang=en_US&edition=fundamental","pubTime":"2023-06-22 23:11","market":"hk","language":"zh","title":"Wall Street can't sit still! New regulations of U.S. banking industry may be tougher than expected","url":"https://stock-news.laohu8.com/highlight/detail?id=2345500717","media":"金十数据","summary":"据六名知情人士透露，美国银行业正推动软化一项提高银行资本金要求的重大监管提案，担心该提案可能过于繁重，尤其是对仍未从3月银行业危机中恢复过来的银行而言。以美联储为首的银行监管机构正在敲定一项提案，该提","content":"<p><html><head></head><body>The U.S. banking industry is pushing to soften a major regulatory proposal to raise capital requirements for banks, according to six people familiar with the matter,<strong>Concerns that the proposal may be too onerous, especially for banks that have still not recovered from the March banking crisis</strong>。</p><p>Banking regulators, led by the Federal Reserve, are finalizing a proposal that would implement international capital standards agreed by the Basel Committee on Banking Supervision after the 2007-2009 financial crisis.</p><p>Bankers are particularly concerned about a proposal in the draft, namely<strong>Higher capital charges on non-interest income</strong>。 Non-interest income such as fees charged by banks for credit cards or investment banking services.</p><p>The demand is part of a package agreed by the Basel Committee in 2017, people familiar with the matter said. But the industry said,<strong>This exaggerates the risks faced by banks with a high share of non-interest income</strong>And hopes U.S. regulators will ease their requirements.</p><p>The banking industry is urging regulators to cap the proportion of assets that such charges apply, but it's unclear whether regulators will take that approach, three people familiar with the matter said.</p><p>An industry insider pointed out that in recent years,<strong>Non-interest service income has been a focus of many banks' growth strategies.</strong></p><p>According to a 2022 blog from the Banking Policy Institute in Washington,<a href=\"https://laohu8.com/S/AXP\">American Express</a>、<a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a>And UBS,<a href=\"https://laohu8.com/S/DB\">Deutsche Bank</a>And Barclays' U.S. subsidiaries are banks with a high proportion of non-interest income.</p><p><a href=\"https://laohu8.com/S/BCS\">Barclays Bank</a>、<a href=\"https://laohu8.com/S/0H7D.UK\">Deutsche Bank</a>And Morgan Stanley declined to comment. UBS and American Express were also not immediately available for comment.</p><p>On Wednesday, Federal Reserve Chair Powell told Congress that it was critical for banks to have deep capital, but that regulators must be mindful of the trade-offs to avoid challenging banks' operations.</p><p><h2><span><span>Beyond expectations harsh</span>Regulation coming? Wall Street shivers!</span></h2>While the Basel agreement was reached years ago, it wasn't until this year's banking crisis that the U.S. began drafting regulatory bills to comply with it. In this crisis, a deposit run led to the collapse of Silicon Valley Bank and two other banks.</p><p>The proposal is the first major rule spearheaded by Barr, the Fed's vice chair for supervision. Barr has launched a comprehensive review of capital rules and is expected to take tough measures against Wall Street.</p><p>Isaac Boltansky, head of policy research at brokerage firm BTIG, said: \"The benchmark assumption has shifted to<strong>The toughness will be far greater than anyone expected at the end of last year</strong>”。</p><p>Banking executives argue that bank failures are caused by mismanagement and liquidity problems, and that the entire system is well-capitalized.</p><p>Three sources said,<strong>The proposal is also expected to let tougher capital rules apply to smaller banks with more than $100 billion in assets, including some that have experienced liquidity problems this year.</strong></p><p>Bankers say increasing capital requirements now could backfire, weighing on the banking sector and hurting credit conditions, given investors' unease about the health of the sector and the overall economy.</p><p>Two people familiar with the matter said<strong>Republican officials have voiced similar concerns</strong>Republican lawmakers similarly raised concerns about capital rules with Powell on Wednesday.</p><p>Kevin Fromer, chief executive of the Financial Services Forum, said it is \"extremely important for regulators to be mindful of economic costs during times of uncertainty\",<strong>\"It is not in the interests of the U.S. economy to raise capital requirements for already well-capitalized institutions\".</strong>Members of the forum include eight of the largest U.S. banks.</p><p>The Federal Reserve is working with the Office of the Comptroller of the Currency (OCC) and the Federal Deposit Insurance Corporation (FDIC) to draft new regulations. Regulators had hoped to unveil the proposal this month, but staff are still drafting the draft, five people familiar with the matter said,<strong>The timetable has been pushed back to late July</strong>。 Both the OCC and the FDIC declined to comment.</p><p>Michael Hsu, the acting comptroller of the U.S. currency, told reporters last week that banks are \"not shy about sharing their concerns\" and that regulators are weighing the risks.</p><p></body></html></p>","source":"xnew_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street can't sit still! New regulations of U.S. banking industry may be tougher than expected</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street can't sit still! New regulations of U.S. banking industry may be tougher than expected\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">金十数据</strong><span class=\"h-time small\">2023-06-22 23:11</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>The U.S. banking industry is pushing to soften a major regulatory proposal to raise capital requirements for banks, according to six people familiar with the matter,<strong>Concerns that the proposal may be too onerous, especially for banks that have still not recovered from the March banking crisis</strong>。</p><p>Banking regulators, led by the Federal Reserve, are finalizing a proposal that would implement international capital standards agreed by the Basel Committee on Banking Supervision after the 2007-2009 financial crisis.</p><p>Bankers are particularly concerned about a proposal in the draft, namely<strong>Higher capital charges on non-interest income</strong>。 Non-interest income such as fees charged by banks for credit cards or investment banking services.</p><p>The demand is part of a package agreed by the Basel Committee in 2017, people familiar with the matter said. But the industry said,<strong>This exaggerates the risks faced by banks with a high share of non-interest income</strong>And hopes U.S. regulators will ease their requirements.</p><p>The banking industry is urging regulators to cap the proportion of assets that such charges apply, but it's unclear whether regulators will take that approach, three people familiar with the matter said.</p><p>An industry insider pointed out that in recent years,<strong>Non-interest service income has been a focus of many banks' growth strategies.</strong></p><p>According to a 2022 blog from the Banking Policy Institute in Washington,<a href=\"https://laohu8.com/S/AXP\">American Express</a>、<a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a>And UBS,<a href=\"https://laohu8.com/S/DB\">Deutsche Bank</a>And Barclays' U.S. subsidiaries are banks with a high proportion of non-interest income.</p><p><a href=\"https://laohu8.com/S/BCS\">Barclays Bank</a>、<a href=\"https://laohu8.com/S/0H7D.UK\">Deutsche Bank</a>And Morgan Stanley declined to comment. UBS and American Express were also not immediately available for comment.</p><p>On Wednesday, Federal Reserve Chair Powell told Congress that it was critical for banks to have deep capital, but that regulators must be mindful of the trade-offs to avoid challenging banks' operations.</p><p><h2><span><span>Beyond expectations harsh</span>Regulation coming? Wall Street shivers!</span></h2>While the Basel agreement was reached years ago, it wasn't until this year's banking crisis that the U.S. began drafting regulatory bills to comply with it. In this crisis, a deposit run led to the collapse of Silicon Valley Bank and two other banks.</p><p>The proposal is the first major rule spearheaded by Barr, the Fed's vice chair for supervision. Barr has launched a comprehensive review of capital rules and is expected to take tough measures against Wall Street.</p><p>Isaac Boltansky, head of policy research at brokerage firm BTIG, said: \"The benchmark assumption has shifted to<strong>The toughness will be far greater than anyone expected at the end of last year</strong>”。</p><p>Banking executives argue that bank failures are caused by mismanagement and liquidity problems, and that the entire system is well-capitalized.</p><p>Three sources said,<strong>The proposal is also expected to let tougher capital rules apply to smaller banks with more than $100 billion in assets, including some that have experienced liquidity problems this year.</strong></p><p>Bankers say increasing capital requirements now could backfire, weighing on the banking sector and hurting credit conditions, given investors' unease about the health of the sector and the overall economy.</p><p>Two people familiar with the matter said<strong>Republican officials have voiced similar concerns</strong>Republican lawmakers similarly raised concerns about capital rules with Powell on Wednesday.</p><p>Kevin Fromer, chief executive of the Financial Services Forum, said it is \"extremely important for regulators to be mindful of economic costs during times of uncertainty\",<strong>\"It is not in the interests of the U.S. economy to raise capital requirements for already well-capitalized institutions\".</strong>Members of the forum include eight of the largest U.S. banks.</p><p>The Federal Reserve is working with the Office of the Comptroller of the Currency (OCC) and the Federal Deposit Insurance Corporation (FDIC) to draft new regulations. Regulators had hoped to unveil the proposal this month, but staff are still drafting the draft, five people familiar with the matter said,<strong>The timetable has been pushed back to late July</strong>。 Both the OCC and the FDIC declined to comment.</p><p>Michael Hsu, the acting comptroller of the U.S. currency, told reporters last week that banks are \"not shy about sharing their concerns\" and that regulators are weighing the risks.</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://xnews.jin10.com/webapp/details.html?id=115509&type=news&data_type=0\">金十数据</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/34f4bf2aa1b8831fa8d83e8683b5b2b6","relate_stocks":{"161125":"标普500","513500":"标普500ETF博时","SQQQ":"纳指三倍做空ETF",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","SH":"做空标普500-Proshares","TQQQ":"纳指三倍做多ETF","SPXU":"三倍做空标普500ETF-ProShares","OCC":"Optical Cable Corporation","BK4504":"桥水持仓","BK4559":"巴菲特持仓",".SPX":"S&P 500 Index","SDOW":"三倍做空道指30ETF-ProShares","DDM":"2倍做多道指ETF-ProShares","BK4550":"红杉资本持仓","BK4588":"碎股","DXD":"两倍做空道琼30指数ETF-ProShares","QLD":"2倍做多纳斯达克100指数ETF-ProShares","SPY":"标普500ETF","QQQ":"纳指100ETF","SDS":"两倍做空标普500 ETF-ProShares","UDOW":"三倍做多道指30ETF-ProShares","SSO":"2倍做多标普500ETF-ProShares","BK4581":"高盛持仓","QID":"两倍做空纳斯达克指数ETF-ProShares","DJX":"1/100道琼斯","IVV":"标普500ETF-iShares","OEX":"标普100","OEF":"标普100指数ETF-iShares","BK4020":"通信设备","PSQ":"做空纳斯达克100指数ETF-ProShares","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","DOG":"道指ETF-ProShares做空","UPRO":"三倍做多标普500ETF-ProShares"},"source_url":"https://xnews.jin10.com/webapp/details.html?id=115509&type=news&data_type=0","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2345500717","content_text":"据六名知情人士透露，美国银行业正推动软化一项提高银行资本金要求的重大监管提案，担心该提案可能过于繁重，尤其是对仍未从3月银行业危机中恢复过来的银行而言。以美联储为首的银行监管机构正在敲定一项提案，该提案将实施巴塞尔银行监管委员会在2007-2009年金融危机后达成的国际资本标准。银行家们尤其担心的是草案中的一项提议，即对非利息收入征收更高的资本费用。非利息收入比如银行对信用卡或投资银行服务收取的费用。知情人士称，这项要求是巴塞尔委员会于2017年达成的一揽子协议的一部分。但业内表示，这夸大了非利息收入占比较高的银行面临的风险，并希望美国监管机构能放松要求。三位知情人士表示，银行业正敦促监管机构对此类收费适用的资产比例设定上限，但尚不清楚监管机构是否会采取这种做法。一位业内人士指出，近年来，非利息服务收入一直是许多银行增长战略的重点。根据华盛顿银行政策研究所2022年的一篇博客，美国运通、摩根士丹利以及瑞银、德意志银行和巴克莱的美国子公司均属于非利息收入占比很高的银行。巴克莱银行、德意志银行和摩根士丹利拒绝就此事置评。瑞银和美国运通也没有立即发表评论。周三，美联储主席鲍威尔告诉国会，银行拥有雄厚的资本至关重要，但监管机构必须注意权衡，以避免银行的业务受到挑战。超预期严厉的监管要来了？华尔街瑟瑟发抖！虽然巴塞尔协议早在几年前就已达成，但直到今年银行业危机爆发后，美国才开始起草监管法案以遵守该协议。在这场危机中，存款挤兑导致硅谷银行和另外两家银行倒闭。该提案是美联储负责监管的副主席巴尔牵头制定的首条重大规则。巴尔已启动了对资本规则的全面评估，预计将对华尔街采取严厉措施。经纪公司BTIG政策研究主管艾萨克•博尔坦斯基（Isaac Boltansky）表示，“基准假设已经转变为，该提案的强硬程度将远远超出去年年底时任何人的预期”。银行业高管辨称，银行倒闭是由管理不善和流动性问题造成的，而且整个系统的资本已经充足。三名消息人士称，该提案预计还将让更严格的资本规则适用于资产超过1000亿美元的小型银行，其中包括一些今年遇到流动性问题的银行。银行家表示，鉴于投资者对该行业和整体经济的健康状况感到不安，现在增加资本金要求可能会适得其反，给银行业带来压力并损害信贷状况。两位知情人士说，监管机构中的共和党官员也表达了类似的担忧，周三共和党议员同样向鲍威尔提出了对资本规则的担忧。金融服务论坛首席执行官凯文·弗罗默（Kevin Fromer）表示，“在充满不确定性的时期，各监管机构要注意经济成本，这一点极其重要”，“对已经资本充足的机构提高资本金要求，不符合美国经济的利益”。该论坛的成员包括美国最大的八家银行。美联储正在与货币监理署（OCC）和联邦存款保险公司（FDIC）一起起草监管新规。五位知情人士表示，监管机构原本希望本月公布该提案，但工作人员仍在起草草案，时间表已推迟到7月下旬。OCC和FDIC都拒绝置评。美国货币代理主计长迈克尔·许（Michael Hsu）上周对记者表示，银行“并不羞于分享他们的担忧”，监管机构正在权衡风险。","news_type":1,"symbols_score_info":{"161125":0.6,"513500":0.6,"SSO":0.6,"MNQmain":0.6,"QLD":0.6,"OEX":0.6,"SQQQ":0.6,"DXD":0.6,"ESmain":0.6,".SPX":0.6,"SH":0.6,"UDOW":0.6,"SPY":0.65,"TQQQ":0.6,"SPXU":0.6,"DOG":0.6,"OEF":0.6,"IVV":0.6,"OCC":1,"QQQ":0.6,"NQmain":0.6,"QID":0.6,".DJI":0.65,"DDM":0.6,"PSQ":0.6,".IXIC":0.65,"DJX":0.6,"SDOW":0.6,"UPRO":0.6,"SDS":0.6}},"isVote":1,"tweetType":1,"viewCount":3996,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190248901304496,"gmtCreate":1687473141791,"gmtModify":1687473145111,"author":{"id":"3583111190875685","authorId":"3583111190875685","name":"lcGoh","avatar":"https://community-static.tradeup.com/news/ea3d27fab7696dea29861dd0ec2eeec9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583111190875685","idStr":"3583111190875685"},"themes":[],"title":"","htmlText":"N","listText":"N","text":"N","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/190248901304496","repostId":"1194491376","repostType":4,"isVote":1,"tweetType":1,"viewCount":3979,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190249367875712,"gmtCreate":1687473122351,"gmtModify":1687473125887,"author":{"id":"3583111190875685","authorId":"3583111190875685","name":"lcGoh","avatar":"https://community-static.tradeup.com/news/ea3d27fab7696dea29861dd0ec2eeec9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583111190875685","idStr":"3583111190875685"},"themes":[],"title":"","htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/190249367875712","repostId":"1133142033","repostType":4,"repost":{"id":"1133142033","kind":"news","pubTimestamp":1687447997,"share":"https://ttm.financial/m/news/1133142033?lang=en_US&edition=fundamental","pubTime":"2023-06-22 23:33","market":"us","language":"zh","title":"Do not hesitate to destroy jobs? POWELL: Two more rate hike is appropriate","url":"https://stock-news.laohu8.com/highlight/detail?id=1133142033","media":"金十数据","summary":"尽管议员质疑美联储抗通胀可能破坏就业，但鲍威尔极力为进一步紧缩的立场辩护，此前又一鹰派现身支持.......周四，美联储主席鲍威尔出席众议院金融服务委员会听证会，发言稿与周三的证词一模一样。在问答环节","content":"<p><html><head></head><body><strong>While lawmakers questioned that the Fed's inflation fight could destroy jobs, Powell vigorously defended the stance of further tightening after another hawk showed up in support of......</strong><p style=\"text-align: justify;\">On Thursday, Federal Reserve Chairman Powell appeared before the House Financial Services Committee in a speech identical to Wednesday's testimony. In the question and answer session,<strong>Powell defended the need for further rate hike, despite the possible implications for employment.</strong></p><p><p style=\"text-align: justify;\">Sen. Sherrod Brown, a Democrat from Ohio and chairman of the Senate Banking Committee, questioned that the Fed's efforts to control inflation threaten to lead to a disproportionate loss of jobs for racial and ethnic minorities. \"Where I live, what the Fed says' calming ordinary people down is laying off jobs.'</p><p><p style=\"text-align: justify;\">In response, Powell said working families will be most directly and quickly affected by inflation. But he added that Fed officials currently believe that \"if the economy performs as expected,<strong>Again this year rate hike would be appropriate, and perhaps rate hike twice</strong>。”</p><p><p style=\"text-align: justify;\">According to it, that committee<strong>The vast majority think interest rates have a little upside</strong>。 Although inflation fell, it was mainly due to lower energy and food prices, not monetary policy (which played a role). He expects the unemployment rate to rise a little further, helping to slow inflation.</p><p><p style=\"text-align: justify;\">Lawmakers also questioned Powell on banking issues. He acknowledged that the Fed needs to strengthen its regulatory and oversight practices,<strong>May raise capital requirements for large banks by 20%.</strong></p><p><p style=\"text-align: justify;\">Earlier on the same day, Fed Gov. Bowman said the Fed needed to raise interest rates further to bring down inflation, which meant she joined the hawks,<strong>It is hoped that rate hike will be restored in due course after leaving interest rates unchanged last week.</strong></p><p><p style=\"text-align: justify;\">Bowman said Thursday in remarks prepared for a Fed listening event in Cleveland:</p><p><strong>\"I support the Federal Open Market Committee's (FOMC) decision last week to keep the Federal Funds rate target range unchanged and continue to cut the securities holdings of the Federal Reserve. However, I believe that further policy rate hikes are necessary over time to bring inflation down to the target level.\"</strong><p style=\"text-align: justify;\">Bowman reiterated Powell's message on Capitol Hill this week. Speaking before the House Finance Committee on Wednesday, he said policymakers anticipate the need to continue raising interest rates to slow U.S. economic growth and curb price pressures.</p><p><p style=\"text-align: justify;\">At the moment, Fed officials are beginning to work on the best way to cool inflation<strong>Create more disagreements</strong>。 While inflation is slowing, it remains above the Fed's 2% target.</p><p><p style=\"text-align: justify;\">ATLANTA Federal Reserve Bank President Bostic said Wednesday that he supports keeping interest rates steady for the rest of the year, giving inflation time to react to past rate hike actions. And Bowman's latest suggestion that further increases in borrowing costs may be needed to bring down core inflation, a measure that has remained high. She said:</p><p><strong>\"Although tighter monetary policy has had some impact on economic activity and inflation to date, we have seen core inflation largely plateau since the fall of 2022. I expect that we will need to raise interest rates further to achieve a tight enough monetary policy stance to bring down inflation effectively and durably.\"</strong></body></html></p>","source":"jssj","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Do not hesitate to destroy jobs? POWELL: Two more rate hike is appropriate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDo not hesitate to destroy jobs? POWELL: Two more rate hike is appropriate\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">金十数据</strong><span class=\"h-time small\">2023-06-22 23:33</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body><strong>While lawmakers questioned that the Fed's inflation fight could destroy jobs, Powell vigorously defended the stance of further tightening after another hawk showed up in support of......</strong><p style=\"text-align: justify;\">On Thursday, Federal Reserve Chairman Powell appeared before the House Financial Services Committee in a speech identical to Wednesday's testimony. In the question and answer session,<strong>Powell defended the need for further rate hike, despite the possible implications for employment.</strong></p><p><p style=\"text-align: justify;\">Sen. Sherrod Brown, a Democrat from Ohio and chairman of the Senate Banking Committee, questioned that the Fed's efforts to control inflation threaten to lead to a disproportionate loss of jobs for racial and ethnic minorities. \"Where I live, what the Fed says' calming ordinary people down is laying off jobs.'</p><p><p style=\"text-align: justify;\">In response, Powell said working families will be most directly and quickly affected by inflation. But he added that Fed officials currently believe that \"if the economy performs as expected,<strong>Again this year rate hike would be appropriate, and perhaps rate hike twice</strong>。”</p><p><p style=\"text-align: justify;\">According to it, that committee<strong>The vast majority think interest rates have a little upside</strong>。 Although inflation fell, it was mainly due to lower energy and food prices, not monetary policy (which played a role). He expects the unemployment rate to rise a little further, helping to slow inflation.</p><p><p style=\"text-align: justify;\">Lawmakers also questioned Powell on banking issues. He acknowledged that the Fed needs to strengthen its regulatory and oversight practices,<strong>May raise capital requirements for large banks by 20%.</strong></p><p><p style=\"text-align: justify;\">Earlier on the same day, Fed Gov. Bowman said the Fed needed to raise interest rates further to bring down inflation, which meant she joined the hawks,<strong>It is hoped that rate hike will be restored in due course after leaving interest rates unchanged last week.</strong></p><p><p style=\"text-align: justify;\">Bowman said Thursday in remarks prepared for a Fed listening event in Cleveland:</p><p><strong>\"I support the Federal Open Market Committee's (FOMC) decision last week to keep the Federal Funds rate target range unchanged and continue to cut the securities holdings of the Federal Reserve. However, I believe that further policy rate hikes are necessary over time to bring inflation down to the target level.\"</strong><p style=\"text-align: justify;\">Bowman reiterated Powell's message on Capitol Hill this week. Speaking before the House Finance Committee on Wednesday, he said policymakers anticipate the need to continue raising interest rates to slow U.S. economic growth and curb price pressures.</p><p><p style=\"text-align: justify;\">At the moment, Fed officials are beginning to work on the best way to cool inflation<strong>Create more disagreements</strong>。 While inflation is slowing, it remains above the Fed's 2% target.</p><p><p style=\"text-align: justify;\">ATLANTA Federal Reserve Bank President Bostic said Wednesday that he supports keeping interest rates steady for the rest of the year, giving inflation time to react to past rate hike actions. And Bowman's latest suggestion that further increases in borrowing costs may be needed to bring down core inflation, a measure that has remained high. She said:</p><p><strong>\"Although tighter monetary policy has had some impact on economic activity and inflation to date, we have seen core inflation largely plateau since the fall of 2022. I expect that we will need to raise interest rates further to achieve a tight enough monetary policy stance to bring down inflation effectively and durably.\"</strong></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://xnews.jin10.com/details/115510\">金十数据</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/b37cbfdbd9fac06fc4ae2f84ad058a92","relate_stocks":{},"source_url":"https://xnews.jin10.com/details/115510","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133142033","content_text":"尽管议员质疑美联储抗通胀可能破坏就业，但鲍威尔极力为进一步紧缩的立场辩护，此前又一鹰派现身支持.......周四，美联储主席鲍威尔出席众议院金融服务委员会听证会，发言稿与周三的证词一模一样。在问答环节，鲍威尔为进一步加息的必要性进行了辩护，尽管这可能对就业产生影响。俄亥俄州民主党参议员、参议院银行委员会主席谢罗德·布朗则质疑道，美联储控制通胀的努力有可能导致少数种族和少数族裔不成比例地失去工作机会。“在我居住的地方，美联储所说的‘让普通人冷静下来就是裁员’。鲍威尔对此表示，工薪家庭将最直接、最迅速地受到通胀的影响。但他补充说，美联储官员目前认为，“如果经济表现如预期，今年再次加息将是合适的，或许还会加息两次。”据其称，委员会中绝大多数人认为利率还有一点上升空间。虽然通胀出现下降，但主要是由于能源和食品价格出现了下降，而非货币政策（起了作用）。他预计失业率将会进一步上升一点，从而帮助减缓通胀。立法者还就银行业问题向鲍威尔提出质询。他承认，美联储需要加强其监管和监督实践，可能将对大型银行的资本要求提高20%。同日早些时候，美联储理事鲍曼表示，美联储需要进一步提高利率以降低通胀，这意味着她加入了鹰派的行列，希望在上周维持利率不变后适时恢复加息。鲍曼周四在为克利夫兰举行的美联储聆听活动准备的讲话中表示：“我支持联邦公开市场委员会（FOMC）上周保持联邦基金利率目标区间不变、并继续削减美联储证券持有量的决定，然而，我认为，随着时间的推移，有必要进一步上调政策利率，以将通胀降至目标水平。”鲍曼重申了鲍威尔本周在国会山传达的信息。他周三在众议院金融委员会发表讲话时表示，政策制定者预计需要继续提高利率，以减缓美国经济增长并遏制价格压力。 当前，美联储官员们开始在冷却通胀的最佳途径上产生更多分歧。虽然通胀正在放缓，但仍高于美联储2%的目标。亚特兰大联邦储备银行行长博斯蒂克周三表示，他支持在今年剩余时间内保持利率稳定，让通胀有时间对过去的加息行动做出反应。而鲍曼最新表示，可能需要进一步提高借贷成本来降低核心通胀，该指标一直居高不下。她说：“尽管迄今为止，紧缩的货币政策对经济活动和通胀产生了一些影响，但我们看到核心通胀自2022年秋季以来基本处于平稳状态。我预计，我们将需要进一步提高利率，以实现足够严格的货币政策立场，从而有效而持久地降低通胀。”","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":3512,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188140677566728,"gmtCreate":1686958515526,"gmtModify":1686958519289,"author":{"id":"3583111190875685","authorId":"3583111190875685","name":"lcGoh","avatar":"https://community-static.tradeup.com/news/ea3d27fab7696dea29861dd0ec2eeec9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583111190875685","idStr":"3583111190875685"},"themes":[],"title":"","htmlText":"H","listText":"H","text":"H","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188140677566728","repostId":"2343195366","repostType":4,"isVote":1,"tweetType":1,"viewCount":3810,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188141469691912,"gmtCreate":1686958496624,"gmtModify":1686958500149,"author":{"id":"3583111190875685","authorId":"3583111190875685","name":"lcGoh","avatar":"https://community-static.tradeup.com/news/ea3d27fab7696dea29861dd0ec2eeec9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583111190875685","idStr":"3583111190875685"},"themes":[],"title":"","htmlText":"N","listText":"N","text":"N","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188141469691912","repostId":"1176607777","repostType":4,"isVote":1,"tweetType":1,"viewCount":3767,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188140553883896,"gmtCreate":1686958478118,"gmtModify":1686958481789,"author":{"id":"3583111190875685","authorId":"3583111190875685","name":"lcGoh","avatar":"https://community-static.tradeup.com/news/ea3d27fab7696dea29861dd0ec2eeec9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583111190875685","idStr":"3583111190875685"},"themes":[],"title":"","htmlText":"O","listText":"O","text":"O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188140553883896","repostId":"1133979930","repostType":4,"repost":{"id":"1133979930","kind":"news","pubTimestamp":1686927123,"share":"https://ttm.financial/m/news/1133979930?lang=en_US&edition=fundamental","pubTime":"2023-06-16 22:52","market":"sh","language":"zh","title":"AbbVie and BeiGene: Can't step into the same river","url":"https://stock-news.laohu8.com/highlight/detail?id=1133979930","media":"氨基观察","summary":"“专利，是给天才之火加上利润之油”，林肯的这句名言，被创新药领域的重磅炸弹药物一次次印证。药企之间，没有什么比一场成功的专利战，更能将对手一击致命。但同时，被狙击的一方，绝不会轻易束手就擒，往往会用尽","content":"<p><html><head></head><body>\"Patent is to add the oil of profit to the fire of genius.\" Lincoln's famous saying has been confirmed again and again by blockbuster drugs in the field of innovative drugs.</p><p><p style=\"text-align: justify;\">Among pharmaceutical companies, nothing can kill an opponent more than a successful patent war. However, at the same time, the side being attacked would never easily surrender and would often use all their strength to resist.</p><p><p style=\"text-align: justify;\">Therefore, more often than not, the start of patent wars means that a tug of war begins. In many cases, the outcome of patent wars is a protracted standoff that ends in reconciliation.</p><p><p style=\"text-align: justify;\">In the past, the protagonists of patent wars were often overseas pharmaceutical companies. However, as domestic pharmaceutical companies play an increasingly important role in the research and development of global innovative drugs, overseas pharmaceutical companies that feel threatened have begun to include domestic pharmaceutical companies in the patent sniper list.</p><p><p style=\"text-align: justify;\">The latest domestic pharmaceutical company to be sniped is<a href=\"https://laohu8.com/S/BGNE\">BeiGene</a>。</p><p><p style=\"text-align: justify;\">On June 15, according to Bloomberg news, AbbVie filed a complaint<a href=\"https://laohu8.com/S/688235\">BeiGene</a>Zebrutinib went to court, alleging that it infringed the patent of ibrutinib.</p><p><p style=\"text-align: justify;\">This does not mean that zanubrutinib necessarily constitutes a fact of infringement. Only, right now<a href=\"https://laohu8.com/S/06160\">BeiGene</a>And AbbVie happens to stand in front of the same opportunity as BTK inhibitors.</p><p><p style=\"text-align: justify;\">In the business world of survival of the fittest, zanubrutinib and ibrutinib cannot step into the same river. And patent sniping was a means that AbbVie had to fight in order to stabilize his position.</p><p><p style=\"text-align: justify;\">Regardless of the outcome, the confrontation between AbbVie and BeiGene is a precious sample for China's innovative drug industry.</p><p><p style=\"text-align: left;\"><strong>/01/</strong></p><p><p style=\"text-align: left;\"><strong>Battle for BTK inhibitors</strong></p><p><p style=\"text-align: justify;\">Since its inception in 2013, sales of AbbVie's BTK inhibitor ibrutinib have skyrocketed. In 2021, ibrutinib was used for AbbVie,<a href=\"https://laohu8.com/S/JNJ\">Johnson & Johnson</a>Bring in a total of $9.8 billion in revenue.</p><p><p style=\"text-align: justify;\">Ibrutinib's super gold-absorbing ability has attracted many players to enter the game, and five BTK inhibitors have been approved for marketing worldwide. Among them, one of the strongest players is Zebrutinib from BeiGene.</p><p><p style=\"text-align: justify;\">At the ASH conference in the United States in 2022, BeiGene announced a phase III clinical trial called ALPINE, which showed that zanubrutinib defeated ibrutinib in head-to-head clinical trials of chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL).</p><p><p style=\"text-align: justify;\">In terms of efficacy, zanubrutinib had a better ORR (78.3% vs. 62.5%) and a higher OS rate (97.0% vs. 92.7%) than ibrutinib. In terms of safety, the incidence of adverse events with atrial fibrillation/atrial flutter was significantly lower in the zanubrutinib group (2.5% vs. 10.19%)</p><p><p style=\"text-align: justify;\">In January this year, with this data, zanubrutinib was approved by the FDA for the treatment of CLL/SLL. In the 2023 NCCN guidelines for the treatment of CLL/SLL, the recommended level of zanubrutinib has been placed ahead of ibrutinib.</p><p><p style=\"text-align: justify;\">You know, CLL/SLL has always been one of the most important indications for ibrutinib. Of the nearly $10 billion in sales of ibrutinib, a large part of the market share comes from the contribution of this field.</p><p><p style=\"text-align: justify;\">Therefore, after zanubrutinib won this indication, Wall Street securities analysts predicted that the peak sales of zanubrutinib may reach $3.1 billion in CLL alone.</p><p><p style=\"text-align: justify;\">Of course, the size of the cake in the CLL/SLL field is certain, and the growth of zanubrutinib sales will inevitably mean that the market share of ibrutinib will be eroded.</p><p><p style=\"text-align: justify;\">In this battle for BTK inhibitors, ibrutinib has gradually shown a decline. In the first quarter, AbbVie's ibrutinib sales fell 25.2% to $878 million.</p><p><p style=\"text-align: justify;\">Nowadays, AbbVie is facing tremendous pressure. In addition to the encirclement and suppression of ibrutinib, the patent of the core product \"Drug King\" Humira has expired, and its market share is also being eroded by generic drugs.</p><p><p style=\"text-align: justify;\">In this case, AbbVie had to launch a counterattack. Therefore, AbbVie came up with its own trump card: patent war.</p><p><p style=\"text-align: left;\"><strong>/02/</strong></p><p><p style=\"text-align: left;\"><strong>An inevitable dispute</strong></p><p><p style=\"text-align: justify;\">In the field of biopharmaceuticals, the most common form of commercial war is patent war.</p><p><p style=\"text-align: justify;\">Because drug patents are closely linked to drug sales, once the patent is broken, it may cause fatal harm to drugs. Therefore, patent litigation has always been a powerful weapon for multinational pharmaceutical companies to block competitors and maintain their market position.</p><p><p style=\"text-align: justify;\">AbbVie was even more familiar with the rules of the patent battle. AbbVie has made many patent layouts around BTK inhibitors and is constantly expanding the scope of protection. This has also become its secret weapon to disrupt the position of competitors.</p><p><p style=\"text-align: justify;\">Back in 2017,<a href=\"https://laohu8.com/S/AZN\">AstraZeneca</a>Shortly after the BTK inhibitor Calaquence was approved for the treatment of mantle cell lymphoma, AbbVie sued Calaquence for infringing its patent.</p><p><p style=\"text-align: justify;\">But AstraZeneca didn't back down, filing a counter-lawsuit against AbbVie in 2018, and after a two-year tug-of-war, AbbVie and AstraZeneca finally reached a settlement that left Calaquence sales unaffected</p><p><p style=\"text-align: justify;\">In addition to BTK inhibitors, AbbVie has also repeatedly come up with the killer of patent war in order to safeguard the rights and interests of \"Medicine King\" Humira.</p><p><p style=\"text-align: justify;\">Although, as early as 2016, the patent protection of Humira's active ingredient has expired, AbbVie has woven a dense patent protective net for the high wall cast for its peripheral patent.</p><p><p style=\"text-align: justify;\">Once a competitor touches Humira's patent protection net, AbbVie will sue to strongly fight back. In the most typical infringement case, AbbVie made 1,600 claims in one breath, directly beating the opponent.</p><p><p style=\"text-align: justify;\">In fact, it is not only Humira and ibrutinib. When we break down the blockbuster drugs around the world, it is not difficult to find that there are more or less cases of patent disputes behind them.</p><p><p style=\"text-align: justify;\">For example, the world's new \"drug king\" K drug.</p><p><p style=\"text-align: justify;\">On September 4, 2014, K drug was approved for marketing in the United States. And on the same day, BMS/Ono will<a href=\"https://laohu8.com/S/MRK\">Merck</a>He went to court, saying that K Drug infringed its PD-1 antibody patent rights.</p><p><p style=\"text-align: justify;\">Although the follow-up K drugs also launched a counterattack, the final winners of this patent war are still BMS and Ono Pharmaceuticals, and Merck needs to distribute the sales of K drugs to them every year.</p><p><p style=\"text-align: justify;\">For example, AstraZeneca/Daiichi Sankyo's DS-8201, Moderna's mRNA technology, CRISPR's gene editing technology and other blockbuster products and technologies have unclear patent disputes behind them.</p><p><p style=\"text-align: justify;\">What is hidden behind the patent dispute is actually the dispute of commercial interests.</p><p><p style=\"text-align: justify;\">To put it bluntly, patent litigation is only a strategy and tool. Maximizing their own interests through continuous patent litigation is the ultimate goal that pharmaceutical companies should achieve in launching patent wars.</p><p><p style=\"text-align: left;\"><strong>/03/</strong></p><p><p style=\"text-align: left;\"><strong>A precious sample</strong></p><p><p style=\"text-align: justify;\">The world is bustling for profit, and the world is bustling for profit. As long as the word \"profit\" is the first, the patent war will never stop.</p><p><p style=\"text-align: justify;\">And how to deal with the complicated patent war is an important study. Although patent war is only a conventional means of commercial war, if it is unfavorably responded to, it may cause great harm to drugs.</p><p><p style=\"text-align: justify;\"><a href=\"https://laohu8.com/S/AMGN\">Amgen</a>With<a href=\"https://laohu8.com/S/0O59.UK\">Sanofi</a>/Regeneron's PCSK9 patent dispute is a good example.</p><p><p style=\"text-align: justify;\">In October 2014, Amgen's Repatha and Sanofi/Regeneron's Praluent PCSK9 monoclonal antibody both submitted marketing applications to the FDA. Because Sanofi used priority review vouchers, Praluent was the first to be approved for marketing.</p><p><p style=\"text-align: justify;\">But Amgen, who followed closely behind, sacrificed a big move, the patent war. In 2014, Amgen sued Sanofi/Regeneron's Praluent for infringing its patents, demanding that Praluent be prohibited from infringing production, use and sale.</p><p><p style=\"text-align: justify;\">Faced with Amgen's sudden blow, Sanofi/Regeneron failed to hold the attack. In 2016, Amgen won a patent lawsuit, and Praluent was kicked out of the US, Japan and European markets one after another. Amgen's Repatha took the opportunity to win 70% of the global market share.</p><p><p style=\"text-align: justify;\">However, Sanofi and Regeneron did not give up, and they continued to appeal to invalidate Regeneron's patent. After several contests, on May 18th, this lawsuit that had been fought for nearly 10 years finally came to an end, and two patents of Amgen's Repatha were invalidated.</p><p><p style=\"text-align: justify;\">While Sanofi/Regeneron won the patent, the blow dealt to Praluent by the patent war has been irreparable. In 2022, Amgen's Repatha sales were approximately $1.3 billion, compared to Sanofi/Regeneron's Praluent sales of just $376 million over the same period.</p><p><p style=\"text-align: justify;\">From this example, we can also see that although launching a patent war is only a common means for big pharmaceutical companies to check and balance their opponents, the challenged can't take it lightly. Once the preparation is not adequate and the challenger takes the upper hand, it can do great harm to drug sales.</p><p><p style=\"text-align: justify;\">Therefore, after the news of AbbVie sniping zanubrutinib came out, the panic of investors was visible to the naked eye. As of the close of trading on June 15th, the share price of BeiGene A shares plummeted 14%.</p><p><p style=\"text-align: justify;\">Although BeiGene will not sit still for AbbVie's sniping, it said that it \"will respond to the complaint in due course and carry out an active defense\", but no one can predict what the final result will be.</p><p><p style=\"text-align: justify;\">Compared with the outcome of the dispute between the two parties, what is more worthy of attention is that if domestic pharmaceutical companies want to seize the European and American markets, they must re-examine the patent issue.</p><p><p style=\"text-align: justify;\">After all, as more and more Chinese innovative pharmaceutical companies begin to go international, in the process, the chances of domestic pharmaceutical companies being attacked by the patents of overseas pharmaceutical companies will also greatly increase.</p><p><p style=\"text-align: justify;\">In terms of patent wars, foreign enterprises often come prepared. Once they feel that their market share is threatened, they will launch fierce patent sniping.</p><p></body></html></p>","source":"lsy1686927134813","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie and BeiGene: Can't step into the same river</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie and BeiGene: Can't step into the same river\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">氨基观察</strong><span class=\"h-time small\">2023-06-16 22:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>\"Patent is to add the oil of profit to the fire of genius.\" Lincoln's famous saying has been confirmed again and again by blockbuster drugs in the field of innovative drugs.</p><p><p style=\"text-align: justify;\">Among pharmaceutical companies, nothing can kill an opponent more than a successful patent war. However, at the same time, the side being attacked would never easily surrender and would often use all their strength to resist.</p><p><p style=\"text-align: justify;\">Therefore, more often than not, the start of patent wars means that a tug of war begins. In many cases, the outcome of patent wars is a protracted standoff that ends in reconciliation.</p><p><p style=\"text-align: justify;\">In the past, the protagonists of patent wars were often overseas pharmaceutical companies. However, as domestic pharmaceutical companies play an increasingly important role in the research and development of global innovative drugs, overseas pharmaceutical companies that feel threatened have begun to include domestic pharmaceutical companies in the patent sniper list.</p><p><p style=\"text-align: justify;\">The latest domestic pharmaceutical company to be sniped is<a href=\"https://laohu8.com/S/BGNE\">BeiGene</a>。</p><p><p style=\"text-align: justify;\">On June 15, according to Bloomberg news, AbbVie filed a complaint<a href=\"https://laohu8.com/S/688235\">BeiGene</a>Zebrutinib went to court, alleging that it infringed the patent of ibrutinib.</p><p><p style=\"text-align: justify;\">This does not mean that zanubrutinib necessarily constitutes a fact of infringement. Only, right now<a href=\"https://laohu8.com/S/06160\">BeiGene</a>And AbbVie happens to stand in front of the same opportunity as BTK inhibitors.</p><p><p style=\"text-align: justify;\">In the business world of survival of the fittest, zanubrutinib and ibrutinib cannot step into the same river. And patent sniping was a means that AbbVie had to fight in order to stabilize his position.</p><p><p style=\"text-align: justify;\">Regardless of the outcome, the confrontation between AbbVie and BeiGene is a precious sample for China's innovative drug industry.</p><p><p style=\"text-align: left;\"><strong>/01/</strong></p><p><p style=\"text-align: left;\"><strong>Battle for BTK inhibitors</strong></p><p><p style=\"text-align: justify;\">Since its inception in 2013, sales of AbbVie's BTK inhibitor ibrutinib have skyrocketed. In 2021, ibrutinib was used for AbbVie,<a href=\"https://laohu8.com/S/JNJ\">Johnson & Johnson</a>Bring in a total of $9.8 billion in revenue.</p><p><p style=\"text-align: justify;\">Ibrutinib's super gold-absorbing ability has attracted many players to enter the game, and five BTK inhibitors have been approved for marketing worldwide. Among them, one of the strongest players is Zebrutinib from BeiGene.</p><p><p style=\"text-align: justify;\">At the ASH conference in the United States in 2022, BeiGene announced a phase III clinical trial called ALPINE, which showed that zanubrutinib defeated ibrutinib in head-to-head clinical trials of chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL).</p><p><p style=\"text-align: justify;\">In terms of efficacy, zanubrutinib had a better ORR (78.3% vs. 62.5%) and a higher OS rate (97.0% vs. 92.7%) than ibrutinib. In terms of safety, the incidence of adverse events with atrial fibrillation/atrial flutter was significantly lower in the zanubrutinib group (2.5% vs. 10.19%)</p><p><p style=\"text-align: justify;\">In January this year, with this data, zanubrutinib was approved by the FDA for the treatment of CLL/SLL. In the 2023 NCCN guidelines for the treatment of CLL/SLL, the recommended level of zanubrutinib has been placed ahead of ibrutinib.</p><p><p style=\"text-align: justify;\">You know, CLL/SLL has always been one of the most important indications for ibrutinib. Of the nearly $10 billion in sales of ibrutinib, a large part of the market share comes from the contribution of this field.</p><p><p style=\"text-align: justify;\">Therefore, after zanubrutinib won this indication, Wall Street securities analysts predicted that the peak sales of zanubrutinib may reach $3.1 billion in CLL alone.</p><p><p style=\"text-align: justify;\">Of course, the size of the cake in the CLL/SLL field is certain, and the growth of zanubrutinib sales will inevitably mean that the market share of ibrutinib will be eroded.</p><p><p style=\"text-align: justify;\">In this battle for BTK inhibitors, ibrutinib has gradually shown a decline. In the first quarter, AbbVie's ibrutinib sales fell 25.2% to $878 million.</p><p><p style=\"text-align: justify;\">Nowadays, AbbVie is facing tremendous pressure. In addition to the encirclement and suppression of ibrutinib, the patent of the core product \"Drug King\" Humira has expired, and its market share is also being eroded by generic drugs.</p><p><p style=\"text-align: justify;\">In this case, AbbVie had to launch a counterattack. Therefore, AbbVie came up with its own trump card: patent war.</p><p><p style=\"text-align: left;\"><strong>/02/</strong></p><p><p style=\"text-align: left;\"><strong>An inevitable dispute</strong></p><p><p style=\"text-align: justify;\">In the field of biopharmaceuticals, the most common form of commercial war is patent war.</p><p><p style=\"text-align: justify;\">Because drug patents are closely linked to drug sales, once the patent is broken, it may cause fatal harm to drugs. Therefore, patent litigation has always been a powerful weapon for multinational pharmaceutical companies to block competitors and maintain their market position.</p><p><p style=\"text-align: justify;\">AbbVie was even more familiar with the rules of the patent battle. AbbVie has made many patent layouts around BTK inhibitors and is constantly expanding the scope of protection. This has also become its secret weapon to disrupt the position of competitors.</p><p><p style=\"text-align: justify;\">Back in 2017,<a href=\"https://laohu8.com/S/AZN\">AstraZeneca</a>Shortly after the BTK inhibitor Calaquence was approved for the treatment of mantle cell lymphoma, AbbVie sued Calaquence for infringing its patent.</p><p><p style=\"text-align: justify;\">But AstraZeneca didn't back down, filing a counter-lawsuit against AbbVie in 2018, and after a two-year tug-of-war, AbbVie and AstraZeneca finally reached a settlement that left Calaquence sales unaffected</p><p><p style=\"text-align: justify;\">In addition to BTK inhibitors, AbbVie has also repeatedly come up with the killer of patent war in order to safeguard the rights and interests of \"Medicine King\" Humira.</p><p><p style=\"text-align: justify;\">Although, as early as 2016, the patent protection of Humira's active ingredient has expired, AbbVie has woven a dense patent protective net for the high wall cast for its peripheral patent.</p><p><p style=\"text-align: justify;\">Once a competitor touches Humira's patent protection net, AbbVie will sue to strongly fight back. In the most typical infringement case, AbbVie made 1,600 claims in one breath, directly beating the opponent.</p><p><p style=\"text-align: justify;\">In fact, it is not only Humira and ibrutinib. When we break down the blockbuster drugs around the world, it is not difficult to find that there are more or less cases of patent disputes behind them.</p><p><p style=\"text-align: justify;\">For example, the world's new \"drug king\" K drug.</p><p><p style=\"text-align: justify;\">On September 4, 2014, K drug was approved for marketing in the United States. And on the same day, BMS/Ono will<a href=\"https://laohu8.com/S/MRK\">Merck</a>He went to court, saying that K Drug infringed its PD-1 antibody patent rights.</p><p><p style=\"text-align: justify;\">Although the follow-up K drugs also launched a counterattack, the final winners of this patent war are still BMS and Ono Pharmaceuticals, and Merck needs to distribute the sales of K drugs to them every year.</p><p><p style=\"text-align: justify;\">For example, AstraZeneca/Daiichi Sankyo's DS-8201, Moderna's mRNA technology, CRISPR's gene editing technology and other blockbuster products and technologies have unclear patent disputes behind them.</p><p><p style=\"text-align: justify;\">What is hidden behind the patent dispute is actually the dispute of commercial interests.</p><p><p style=\"text-align: justify;\">To put it bluntly, patent litigation is only a strategy and tool. Maximizing their own interests through continuous patent litigation is the ultimate goal that pharmaceutical companies should achieve in launching patent wars.</p><p><p style=\"text-align: left;\"><strong>/03/</strong></p><p><p style=\"text-align: left;\"><strong>A precious sample</strong></p><p><p style=\"text-align: justify;\">The world is bustling for profit, and the world is bustling for profit. As long as the word \"profit\" is the first, the patent war will never stop.</p><p><p style=\"text-align: justify;\">And how to deal with the complicated patent war is an important study. Although patent war is only a conventional means of commercial war, if it is unfavorably responded to, it may cause great harm to drugs.</p><p><p style=\"text-align: justify;\"><a href=\"https://laohu8.com/S/AMGN\">Amgen</a>With<a href=\"https://laohu8.com/S/0O59.UK\">Sanofi</a>/Regeneron's PCSK9 patent dispute is a good example.</p><p><p style=\"text-align: justify;\">In October 2014, Amgen's Repatha and Sanofi/Regeneron's Praluent PCSK9 monoclonal antibody both submitted marketing applications to the FDA. Because Sanofi used priority review vouchers, Praluent was the first to be approved for marketing.</p><p><p style=\"text-align: justify;\">But Amgen, who followed closely behind, sacrificed a big move, the patent war. In 2014, Amgen sued Sanofi/Regeneron's Praluent for infringing its patents, demanding that Praluent be prohibited from infringing production, use and sale.</p><p><p style=\"text-align: justify;\">Faced with Amgen's sudden blow, Sanofi/Regeneron failed to hold the attack. In 2016, Amgen won a patent lawsuit, and Praluent was kicked out of the US, Japan and European markets one after another. Amgen's Repatha took the opportunity to win 70% of the global market share.</p><p><p style=\"text-align: justify;\">However, Sanofi and Regeneron did not give up, and they continued to appeal to invalidate Regeneron's patent. After several contests, on May 18th, this lawsuit that had been fought for nearly 10 years finally came to an end, and two patents of Amgen's Repatha were invalidated.</p><p><p style=\"text-align: justify;\">While Sanofi/Regeneron won the patent, the blow dealt to Praluent by the patent war has been irreparable. In 2022, Amgen's Repatha sales were approximately $1.3 billion, compared to Sanofi/Regeneron's Praluent sales of just $376 million over the same period.</p><p><p style=\"text-align: justify;\">From this example, we can also see that although launching a patent war is only a common means for big pharmaceutical companies to check and balance their opponents, the challenged can't take it lightly. Once the preparation is not adequate and the challenger takes the upper hand, it can do great harm to drug sales.</p><p><p style=\"text-align: justify;\">Therefore, after the news of AbbVie sniping zanubrutinib came out, the panic of investors was visible to the naked eye. As of the close of trading on June 15th, the share price of BeiGene A shares plummeted 14%.</p><p><p style=\"text-align: justify;\">Although BeiGene will not sit still for AbbVie's sniping, it said that it \"will respond to the complaint in due course and carry out an active defense\", but no one can predict what the final result will be.</p><p><p style=\"text-align: justify;\">Compared with the outcome of the dispute between the two parties, what is more worthy of attention is that if domestic pharmaceutical companies want to seize the European and American markets, they must re-examine the patent issue.</p><p><p style=\"text-align: justify;\">After all, as more and more Chinese innovative pharmaceutical companies begin to go international, in the process, the chances of domestic pharmaceutical companies being attacked by the patents of overseas pharmaceutical companies will also greatly increase.</p><p><p style=\"text-align: justify;\">In terms of patent wars, foreign enterprises often come prepared. Once they feel that their market share is threatened, they will launch fierce patent sniping.</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://mp.weixin.qq.com/s?__biz=MzIwMjU5Njk5NA==&mid=2247496324&idx=1&sn=368b858aadaf3d6665d1cbe72af1cf78&chksm=96de8569a1a90c7f4700ab1c97d8f4794355914f5d6c19d7ecd88ac9a0d32cba49ceb8929d32#rd\">氨基观察</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/3771c3d94c1c3544b07a5dcf5fabd2ee","relate_stocks":{"688235":"百济神州","BK1588":"回港中概股","BK1161":"生物科技","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK4585":"ETF&股票定投概念","BK4526":"热门中概股","BK1583":"高瓴概念","BK0239":"医药制造","BK4139":"生物科技","BK4505":"高瓴资本持仓","BK4535":"淡马锡持仓","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK4504":"桥水持仓","BK4588":"碎股","06160":"百济神州","BK1500":"做空集合股","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK4548":"巴美列捷福持仓","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD"},"source_url":"https://mp.weixin.qq.com/s?__biz=MzIwMjU5Njk5NA==&mid=2247496324&idx=1&sn=368b858aadaf3d6665d1cbe72af1cf78&chksm=96de8569a1a90c7f4700ab1c97d8f4794355914f5d6c19d7ecd88ac9a0d32cba49ceb8929d32#rd","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133979930","content_text":"“专利，是给天才之火加上利润之油”，林肯的这句名言，被创新药领域的重磅炸弹药物一次次印证。药企之间，没有什么比一场成功的专利战，更能将对手一击致命。但同时，被狙击的一方，绝不会轻易束手就擒，往往会用尽了全力反抗。所以，更多时候，专利战的开打，意味着一场拉锯战就此开始。不少情况下，专利战的结局都是，旷日持久的对峙后以和解告终。过往，专利战的主角往往是海外药企。但随着国内药企，在全球创新药研发中的地位越来越重要，感受到威胁的海外药企，开始将国内药企纳入专利狙击名单。最新被狙击的国内药企是百济神州。6月15日，据彭博社消息，艾伯维一纸诉状将百济神州的泽布替尼诉至公堂，称其侵犯了伊布替尼的专利。这并不意味着泽布替尼一定构成侵权事实。只是，当下百济神州和艾伯维恰好站在了，BTK抑制剂这同一个机遇面前。在优胜劣汰的商业世界，泽布替尼和伊布替尼无法踏进同一条河流。而专利狙击，是艾伯维为了稳固自身地位，必须打出的手段。不管结果如何，对中国创新药行业而言，艾伯维与百济神州的对垒，都是一个珍贵的样本。/ 01 /BTK抑制剂争夺战自2013年问世以来，艾伯维的BTK抑制剂伊布替尼销售额一路狂奔。2021年，伊布替尼为艾伯维、强生带来了总计98亿美元的收入。伊布替尼超强的吸金能力，吸引了众多选手入局，全球已有5款BTK抑制剂获批上市。其中，实力最强劲的选手之一，是百济神州的泽布替尼。2022年在美国ASH大会上，百济神州公布的一项名为ALPINE的三期临床试验显示，在慢性淋巴细胞白血病 (CLL) /小淋巴细胞淋巴瘤 (SLL) 的头对头临床试验中，泽布替尼击败了伊布替尼。在疗效上，与伊布替尼相比泽布替尼具有更好的ORR（78.3% vs. 62.5%），更高的OS率（97.0% vs. 92.7%）。在安全性上，泽布替尼组出现房颤/房扑的不良事件发生率显著降低（2.5% vs. 10.19%）今年1月，凭借这一数据，泽布替尼获FDA批准用于治疗CLL/SLL。在2023年的NCCN 治疗CLL/SLL指南中，泽布替尼的推荐级别已被置于伊布替尼之前。要知道，CLL/SLL一直是伊布替尼的最为重要的适应症之一。在伊布替尼近100亿美元的销售额中，有一大部分的市场份额均来自这一领域的贡献。因此，在泽布替尼拿下这一适应症后，华尔街的证券分析师预测，仅在CLL一个适应症上，泽布替尼的销售额峰值就可能达到31亿美元。当然了，CLL/SLL领域蛋糕大小是确定的，泽布替尼销售额的增长，必然意味着伊布替尼市场份额受到蚕食。在这场BTK抑制剂的争夺战中，伊布替尼已经逐渐显露出颓势。一季度，艾伯维的伊布替尼销售额下滑25.2%，为8.78亿美元。如今的艾伯维，正面临巨大压力。除了伊布替尼遭受围剿外，核心产品“药王”修美乐专利到期，市场份额也在被仿制药蚕食。在这种情况下，艾伯维不得不发起反击。所以，艾伯维拿出了自己的杀手锏：专利战。/ 02 /必然发生的纠纷在生物制药领域，最常见的商战形式便是专利战。因为药物专利和药物的销售情况紧紧相连，一旦攻破专利可能给药物带来致命伤害。所以专利诉讼一直是跨国药企阻击竞争对手、维持市场地位的有力武器。而艾伯维，更是深谙专利之战的规则。围绕BTK抑制剂，艾伯维做了诸多专利布局，且在不断扩大保护范围。这也成为其搅乱竞争对手阵脚的秘密武器。早在2017年，阿斯利康的BTK抑制剂 Calaquence获批治疗套细胞淋巴瘤后不久，艾伯维便起诉Calaquence侵犯了自己的专利。但阿斯利康没有退却，在2018年对艾伯维提起了反诉讼，经过两年的拉锯后，艾伯维和阿斯利康最终达成了和解，Calaquence的销售并未受到影响BTK抑制剂之外，艾伯维也曾为维护“药王”修美乐的权益，多次拿出专利战这一杀手锏。虽然，早在2016年修美乐活性成分的专利保护已经过期，但艾伯维为其外围专利铸造的高墙，编织了一张致密的专利防护网。一旦有竞争对手触碰到修美乐的专利防护网，艾伯维就会诉讼予以强烈反击。最典型的侵权案例中，艾伯维一口气提出了1600个权利要求，直接把对手打蒙。事实上，不仅仅是修美乐和伊布替尼，当我们细数全球的重磅炸弹药物后，不难发现其背后多多少少都有着专利纠纷的案例。比如，全球新任“药王”K药。2014年9月4日，K药在美国获批上市。而就在同一天，BMS/小野制药将默沙东告上了法庭，称K药侵犯了其PD-1抗体专利权。虽然，后续K药也进行了反攻，但最终这场专利战的胜者仍然是BMS和小野制药，默沙东需要每年向二者分红K药的销售额。再比如阿斯利康/第一三共的DS-8201、Moderna的mRNA技术、CRISPR的基因编辑技术等重磅产品、技术背后都有着厘不清的专利纠纷。专利纠纷背后隐藏的，实则是商业利益之争。直白地说，专利诉讼只是策略和工具，通过不断专利诉讼战将自己的利益最大化，这才是药企发动专利战要达到的最终目的。/ 03 /珍贵的样本天下熙熙皆为利来，天下攘攘皆为利去，只要“利”字当头，专利战就永远不会停歇。而如何应对纷繁的专利战，是一门重要的学问。虽然专利战只是一种常规商战手段，但倘若应对不利，可能使药物受到巨大的伤害。安进与赛诺菲/再生元的PCSK9的专利之争，便是一个很好的例子。2014年10月，安进的Repatha和赛诺菲/再生元的Praluent PCSK9单抗都向FDA提交上市申请。由于赛诺菲使用了优先审评券，所以Praluent率先获批上市。但紧随其后的安进祭出了大招，专利战。2014年安进状告赛诺菲/再生元的Praluent侵犯了其拥有的专利，要求禁止Praluent侵权生产、使用和销售。面对着安进突如其来的一击，赛诺菲/再生元没能成功守住攻击。2016年，安进赢得了专利诉讼，Praluent被相继踢出美国、日本、欧洲市场。安进的Repatha则借机赢得了全球70%的市场份额。不过，赛诺菲、再生元并未放弃，二者继续上诉要求无效再生元的专利。经过几番较量，5月18日，这场打了将近10年的官司终于落下帷幕，安进的Repatha两项专利被判无效。虽然赛诺菲/再生元赢了专利，但专利战对Praluent造成的打击已经无法挽回。2022年，安进的Repatha销售额约为13亿美元，而同期赛诺菲/再生元的Praluent销售额仅为3.76亿美元。从这个例子我们也能看到，虽然发起专利战只是大药企制衡对手的惯用手段，但被挑战者并不能就此掉以轻心。一旦准备不充分，被挑战者占据了上风，会对药物销售造成巨大的伤害。所以，在艾伯维狙击泽布替尼消息传出后，投资者的恐慌肉眼可见。截止6月15日收盘，百济神州A股股价大跌14%。虽然百济神州对于艾伯维的狙击也不会坐以待毙，其表示“将在适当的时候对该投诉作出应对，并开展积极的辩护”，但谁也无法预料到最终的结果将会如何。相比于双方纠纷的结果，更值得关注的一点是：国内药企要想去抢占欧美市场，必须重新审视专利问题。毕竟，随着越来越多中国的创新药企开始走向国际，在这个过程中，国内药企被遭到海外药企专利狙击的机会，也会大大增加。而在专利战方面，国外企业往往有备而来，它们一旦感受到市场份额受到威胁时，便会发动猛烈地专利狙击。","news_type":1,"symbols_score_info":{"688235":0.9,"BGNE":0.9,"06160":0.9}},"isVote":1,"tweetType":1,"viewCount":3746,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188141309186200,"gmtCreate":1686958460457,"gmtModify":1686958464404,"author":{"id":"3583111190875685","authorId":"3583111190875685","name":"lcGoh","avatar":"https://community-static.tradeup.com/news/ea3d27fab7696dea29861dd0ec2eeec9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583111190875685","idStr":"3583111190875685"},"themes":[],"title":"","htmlText":"M","listText":"M","text":"M","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188141309186200","repostId":"2343198417","repostType":4,"isVote":1,"tweetType":1,"viewCount":4112,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188140495925296,"gmtCreate":1686958439577,"gmtModify":1686958443110,"author":{"id":"3583111190875685","authorId":"3583111190875685","name":"lcGoh","avatar":"https://community-static.tradeup.com/news/ea3d27fab7696dea29861dd0ec2eeec9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583111190875685","idStr":"3583111190875685"},"themes":[],"title":"","htmlText":"N","listText":"N","text":"N","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188140495925296","repostId":"1165534285","repostType":4,"isVote":1,"tweetType":1,"viewCount":4402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":true}